DA Davidson raised the firm’s price target on Prestige Consumer (PBH) to $104 from $95 and keeps a Buy rating on the shares. The firm cites the company’s Q3 sales and earnings beats, with Summer’s Eve sales up from last year and Clear Eyes shipments up sequentially, the analyst tells investors in a research note. DA Davidson is also rolling forward its valuation model, raising the free cash flow growth rate to 3% from 1% in FY28-FY31, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBH:
- What’s in Your Medicine Cabinet? It’s likely Prestige Consumer Healthcare (PBH) Products
- Prestige Consumer Healthcare Reports Record Earnings Despite Challenges
- Prestige Consumer price target raised to $100 from $93 at Canaccord
- Prestige Consumer Healthcare Reports Stable Earnings Growth
- Prestige Consumer Healthcare Reports Q3 2024 Financial Growth